Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jamie B Elliott
Observed name:
Jamie Elliott
Institutions:
Mayo Clinic,
Mayo Clinic in Florida,
Mayo Clinic Comprehensive Cancer Center (Florida)
Observed institutions:
Mayo Clinic,
Mayo Clinic in Florida,
Mayo Clinic Comprehensive Cancer Center (Florida)
OpenAlex ID:
A5006772932
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities
2024
·
Sikander Ailawadhi
, Yaw Adu
, et al.
·
Blood Cancer Journal
·
11
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
2024
·
Ricardo D. Parrondo
, Betsy R. LaPlant
, et al.
·
Blood Cancer Journal
·
7
PDF
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
2024
·
Ricardo D. Parrondo
, Navnita Dutta
, et al.
·
British Journal of Haematology
·
4
PDF
Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
2022
·
Sikander Ailawadhi
, Ricardo D Parrondo
, et al.
·
Blood
·
4
Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
2022
·
Sikander Ailawadhi
, Ricardo D Parrondo
, et al.
·
Blood
·
4
Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2024
·
Ricardo D. Parrondo
, Saurav Das
, et al.
·
Blood
P-412 Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience
2024
·
Ricardo Parrondo
, Saurav Das
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
7
Citation count:
30
H-index:
4
I10-index:
1
Year
Topic
Type
